A venture capital firm with offices in Palo Alto and California backs entrepreneurs applying deep and differentiated technology to transform giant industries. The firm focuses on seed and series A investments and has over $2B AUM. The firm usually makes seed investments in the range of $250K – $1M and venture-stage investments from $1M-$4M and may use both convertible notes or straight equity. The firm may lead or co-invest in a syndicate and looks to add unique value to entrepreneurs with a strong Equity Partner network, operational experience and technical background.

The firm invests in several verticals and is focused on deep technologies such as AI, advanced materials, quantum computing, etc. In the healthcare space, the firm is focused on the entire continuum including computational drug discovery, AI-driven diagnostics, better/faster clinical trials and technologies used by payers and providers to better understand and manage risk and drive better outcomes. The common theme is that the startup’s underlying technology be novel and data-driven. The firm is also interested in synthetic biology. The firm does not invest in biopharma or traditional medical devices/diagnostics with a standard regulatory pathway.

The firm requires that startups have some type of proof-of concept and traction, and prefers experienced/proven management teams and entrepreneurs that are introduced through the firm’s network. The firm typically seeks a board seat when leading an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A single family office founded in 2009 and based in Toronto is now looking to expand into the healthcare sector and plans to initially invest approximately $10M into seed-stage deals in the healthcare space and may potentially reserve another pool of capital for additional healthcare investments in the future. The firm has flexibility with deal structures and may make either straight equity or convertible loan investments depending on the deal. In addition to capital, the group looks to add value to portfolio companies through marketing and sales expertise. The firm has no specific number of healthcare investments it’s looking to make.

Within healthcare, the firm is focused on the medtech, diagnostic and health IT space. The firm is particularly interested in newly created or accessible markets such as leveraging smart phones, big data/data mining and AI for healthcare purposes. The firm is highly interested in mobile diagnostic devices, diagnostics for the consumer market and portable lab devices. The firm will also look at more traditional FDA regulated medical devices and diagnostics on a secondary basis.

The firm seeks companies addressing specific markets, but has no set requirements for entrepreneurs/management teams other than a very focused team that is passionate about the tech and market being pursued. The firm typically seeks a board seat along with in an investment, but may not require one depending on the terms of the deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Founded in 2006, a specialized healthcare and life sciences investment firm with over a half-billion dollars in capital under management will close their fourth fund in 2021. The firm invests in early-stage companies (Seed/Series A) developing innovative new medical technologies, biotechnologies, and digitally-enabled healthcare services. The firm generally invests $4-8 million of equity capital per round and up to $10-20 million over the investment life. The firm is actively investing and will make 3-5 investments in 2021.The firm invests nationally and has offices in Austin, TX, and Boston, MA.

The firm is currently looking for companies developing Medical Devices, Therapeutics, Diagnostics, and Healthcare IT products. For medical devices and therapeutics, the firm is open to the full spectrum of subsector and indication and will consider companies developing orphan indications. In HealthTech, the firm is interested in AI-enabled clinical/diagnostic/workflow platforms but will also consider other companies that fall into the broader Healthcare IT space as well, including mobile health companies developing consumer-facing apps. They will consider companies with proprietary platform technologies as well as single/multiple asset companies.

As an early-stage investor, the firm invests almost exclusively in pre-revenue companies, with significant ownership opportunities. They look for experienced management teams, help build the team, and require a seat on the company’s board.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.